Effects of Individualized PEEP Guided by Driving Pressure on Postoperative Atelectasis in Patients With Morbid Obesity
Launched by YONGTAO SUN · Dec 12, 2023
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a method to help prevent a common problem called atelectasis, which is when parts of the lungs collapse after surgery. This issue can be especially concerning for patients with severe obesity who are undergoing bariatric surgery. The trial will look at whether using a specific approach called driving pressure guided PEEP (a way to adjust breathing support) can reduce the risk of atelectasis after surgery.
To participate in this study, you need to be between 18 and 60 years old and have a body mass index (BMI) of 40 or higher, which indicates severe obesity. You should also be in good overall health, without serious respiratory or other significant health issues. If you decide to join, you will be randomly assigned to receive either the new approach or standard care during your surgery. This trial is currently recruiting participants, and it's important to understand that your well-being will be closely monitored throughout the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 to 60 years old;
- • Body mass index (BMI) ≥ 40 kg/m2;
- • ASA classification I to III;
- • Signing the informed consent form for this clinical study;
- Exclusion Criteria:
- • Respiratory infection within 4 weeks; severe respiratory system diseases; history of pulmonary and/or thoracic surgery; neuromuscular dysfunction;
- • Serious cardiac, renal or haematopoietic diseases;
- • Contraindications to PEEP;
About Yongtao Sun
Yongtao Sun is a distinguished clinical trial sponsor recognized for advancing medical research through innovative study designs and rigorous methodologies. With a commitment to enhancing patient care and outcomes, Yongtao Sun leads initiatives across various therapeutic areas, collaborating with healthcare professionals and institutions to ensure the highest standards of ethical conduct and scientific integrity. The organization is dedicated to fostering a collaborative environment that accelerates the development of safe and effective therapies, ultimately contributing to the improvement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jinan, Shandong, China
Patients applied
Trial Officials
yong t Sun, Ph.D
Study Chair
Shandong First Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported